Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:SRRA Sierra Oncology (SRRA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Sierra Oncology Stock (NASDAQ:SRRA) 30 days 90 days 365 days Advanced Chart Ad DTIWhy buying gold might be a mistakeSomething strange just happened with gold. With the recent Fed rate cut… My charts are showing a breakout signal I haven't seen in years. But for now, I'm not rushing to buy gold. In fact, I'm telling everyone I know to hold off. Because I believe there’s a far better way to play this upcoming surge. It's a method that could turn a 1% gold price change into gains like 59%, 118%, or even 228%. And it doesn't involve buying a single ounce of physical gold or even buying any regular gold stock. I've been trading gold for nearly 20 years now and this is my #1 recommended approach for trading gold right now. Most traders miss them completely… But for those who know how to spot them, it takes their trades to a whole new level.If you're interested, check out the recording here while the link's still up. Get Sierra Oncology alerts:Sign Up Key Stats Today's Range$54.99▼$54.9950-Day Range$54.73▼$54.9952-Week Range$14.91▼$55.19VolumeN/AAverage Volume931,731 shsMarket Capitalization$1.34 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewSierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California.Read More… Why buying gold might be a mistake (Ad)Something strange just happened with gold. With the recent Fed rate cut… My charts are showing a breakout signal I haven't seen in years. But for now, I'm not rushing to buy gold. In fact, I'm telling everyone I know to hold off. Because I believe there’s a far better way to play this upcoming surge. It's a method that could turn a 1% gold price change into gains like 59%, 118%, or even 228%. And it doesn't involve buying a single ounce of physical gold or even buying any regular gold stock. I've been trading gold for nearly 20 years now and this is my #1 recommended approach for trading gold right now. Most traders miss them completely… But for those who know how to spot them, it takes their trades to a whole new level.If you're interested, check out the recording here while the link's still up. Receive SRRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sierra Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address SRRA Stock News HeadlinesSierra Space eyes IPO market as it braces for a 'profound industrial revolution' in spaceApril 11, 2024 | msn.comSierra Oncology Inc.February 21, 2024 | thestreet.comTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… November 13, 2024 | Crypto 101 Media (Ad)Sierra Coupon for OctoberNovember 9, 2023 | time.comFDA approves GSK's unique myelofibrosis treatment OjjaaraSeptember 18, 2023 | msn.comPleasant Surprise For GSK: FDA Approves Bone Marrow Cancer Therapy Acquired Via Sierra Oncology DealSeptember 18, 2023 | msn.comFDA approves GSK's Ojjaara for treatment of myelofibrosis-related anaemiaSeptember 18, 2023 | msn.comAnalyst calls of the week: Palo Alto upped, Carnival earnings preview and moreJune 16, 2023 | proactiveinvestors.comSee More Headlines SRRA Stock Analysis - Frequently Asked Questions How were Sierra Oncology's earnings last quarter? Sierra Oncology, Inc. (NASDAQ:SRRA) announced its quarterly earnings data on Friday, November, 5th. The biotechnology company reported ($2.10) earnings per share for the quarter, missing analysts' consensus estimates of ($1.78) by $0.32. What other stocks do shareholders of Sierra Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sierra Oncology investors own include Onconova Therapeutics (ONTX), VBI Vaccines (VBIV), T2 Biosystems (TTOO), OPKO Health (OPK), Tonix Pharmaceuticals (TNXP), Trevena (TRVN) and Inovio Pharmaceuticals (INO). Company Calendar Last Earnings11/05/2021Today11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:SRRA Previous SymbolNASDAQ:DNAI CUSIPN/A CIK1290149 Webwww.sierraoncology.com Phone(604) 558-6536FaxN/AEmployees109Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($6.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-94,660,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-111.88% Return on Assets-100.01% Debt Debt-to-Equity Ratio0.02 Current Ratio21.27 Quick Ratio21.27 Sales & Book Value Annual Sales$300,000.00 Price / Sales4,476.00 Cash FlowN/A Price / Cash FlowN/A Book Value$6.16 per share Price / Book8.93Miscellaneous Outstanding Shares24,419,000Free Float13,650,000Market Cap$1.34 billion OptionableOptionable Beta0.03 Social Links The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report This page (NASDAQ:SRRA) was last updated on 11/13/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredYou just voted for a financial crisisI’d like to share with you my #1 high-conviction stock to buy before Inauguration Day… and details on the asse...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sierra Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sierra Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.